Biovitrum, Glaxo End Obesity Alliance For Serotonin-Focused Drugs
This article was originally published in The Pink Sheet Daily
Glaxo returns rights on serotonin receptor agonists to the Swedish company, which will not develop them further for obesity.
You may also be interested in...
Safety monitoring board review of echocardiographic data gives firm a green light to continue with pivotal trial.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.